1Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571)induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 2000, 96(6): 2246-2253.
2Bhatia R, Holtzl M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylatetreatment. Blood, 2003, 101(12): 4701-4707.
3Rosee PL, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia,2002,16(
4Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosomepositive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101 (1):97-
6Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent,Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002, 99(1):319 325.
7Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resisitence to imatinib (STI571)therapy. Leukemia, 2002, 16(11): 2190-2196.
8Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol, 2003, 40(1): 50-58.
9Hoover RR, Mahon F-X, Melo JV, et al. Overcoming STI571resistence with the farnesyltransferase inhibitor SCH66366.Blood, 2001, 98(part 1): 617a.
10Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide(As2O3) in the treatment of acute promyelocytic leukemia(APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89(9): 3345-3353.
